Corrigendum to “Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis” [Biomed. Pharmacother. 98 (2018) 382–389]
Ya-Min Tang,
Qing-Yun Cao,
Xing-Yu Guo,
Shui-Hua Dong,
Jin-Ao Duan,
Qi-Nan Wu,
Qiao-Li Liang
Affiliations
Ya-Min Tang
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Qing-Yun Cao
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Xing-Yu Guo
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Shui-Hua Dong
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Jin-Ao Duan
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Qi-Nan Wu
Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
Qiao-Li Liang
Correspondence to: School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Rd., Nanjing 210023, China.; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing, University of Chinese Medicine, Nanjing 210000, China
